Vericel (NASDAQ:VCEL – Get Free Report)‘s stock had its “outperform” rating reissued by equities research analysts at Leerink Partnrs in a report issued on Monday, PriceTargets.com reports. Leerink Partnrs also issued estimates for Vericel’s Q1 2024 earnings at ($0.10) EPS, Q2 2024 earnings at ($0.02) EPS, Q3 2024 earnings at $0.00 EPS, Q4 2024 earnings at $0.30 EPS and FY2024 earnings at $0.20 EPS.
Several other brokerages also recently commented on VCEL. HC Wainwright raised their target price on Vericel from $41.00 to $44.50 and gave the company a “buy” rating in a report on Thursday, September 21st. SVB Leerink started coverage on Vericel in a report on Monday. They set an “outperform” rating and a $42.00 target price on the stock. Stephens reiterated an “overweight” rating and set a $44.00 target price on shares of Vericel in a report on Thursday, September 21st. BTIG Research upgraded Vericel from a “neutral” rating to a “buy” rating and set a $39.00 target price on the stock in a report on Tuesday, August 8th. Finally, Truist Financial reiterated a “hold” rating and set a $39.00 target price on shares of Vericel in a report on Thursday, September 21st. Two research analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. According to MarketBeat.com, Vericel has a consensus rating of “Moderate Buy” and an average price target of $41.70.
View Our Latest Stock Analysis on Vericel
Vericel Price Performance
Vericel (NASDAQ:VCEL – Get Free Report) last released its quarterly earnings data on Wednesday, August 2nd. The biotechnology company reported ($0.11) EPS for the quarter, topping analysts’ consensus estimates of ($0.13) by $0.02. The company had revenue of $45.92 million for the quarter, compared to the consensus estimate of $42.14 million. Vericel had a negative return on equity of 6.90% and a negative net margin of 7.39%. The company’s quarterly revenue was up 24.7% compared to the same quarter last year. During the same period last year, the business posted ($0.19) EPS. Research analysts anticipate that Vericel will post -0.25 EPS for the current year.
Institutional Investors Weigh In On Vericel
A number of hedge funds have recently bought and sold shares of the business. BlackRock Inc. grew its stake in Vericel by 2.7% during the 2nd quarter. BlackRock Inc. now owns 7,632,598 shares of the biotechnology company’s stock valued at $286,757,000 after purchasing an additional 201,157 shares in the last quarter. Brown Capital Management LLC grew its position in shares of Vericel by 1.6% in the 1st quarter. Brown Capital Management LLC now owns 7,042,113 shares of the biotechnology company’s stock worth $206,475,000 after acquiring an additional 110,472 shares in the last quarter. State Street Corp grew its position in shares of Vericel by 15.6% in the 2nd quarter. State Street Corp now owns 3,400,735 shares of the biotechnology company’s stock worth $85,631,000 after acquiring an additional 458,219 shares in the last quarter. RTW Investments LP grew its position in shares of Vericel by 6.2% in the 1st quarter. RTW Investments LP now owns 3,291,873 shares of the biotechnology company’s stock worth $96,518,000 after acquiring an additional 191,969 shares in the last quarter. Finally, Vanguard Group Inc. grew its position in shares of Vericel by 2.8% in the 3rd quarter. Vanguard Group Inc. now owns 3,234,095 shares of the biotechnology company’s stock worth $75,031,000 after acquiring an additional 88,923 shares in the last quarter.
About Vericel
Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in the United States. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; and Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns.
Featured Articles
- Five stocks we like better than Vericel
- 3 Grocery Stocks That Are Proving They Are Still Essential
- Analysts Recommend These Stocks To Cushion The Automotive Slump
- High Dividend REITs: Are They an Ideal Way to Diversify?
- Hyatt Hotels Earning Analysts Love, Buy The Dip?
- What is the Hang Seng index?
- Business is Good for Lockheed Martin; Shares are Ready to Soar.
Receive News & Ratings for Vericel Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vericel and related companies with MarketBeat.com's FREE daily email newsletter.
